|
|
 |
|
Viewing report
|
|
|
|
Licensing Strategies: Benchmarking Analysis of the Top 20 Pharmaceutical Companies
Datamonitor, May 2003, Pages: 177
Licensing is playing an increasing role in the business models of pharmaceutical and biotechnology companies. In 2001, 16.4 per cent of sales from the top 20 pharmaceutical company sales were derived from inlicensed drugs, equal to approximately $38 billion.
However, pharmaceutical and biotechnology companies alike must improve all stages of their licensing deals - from deal identification through to management - to reduce the current rate of attrition, estimated to be over 50 per cent by senior pharmaceutical executives interviewed.
The art of conducting successful licensing is a particularly difficult one to perfect. However, doing so is of critical importance to the industry. Considering the complex nature of deal structures, the many barriers and obstacles to deal management and the overwhelming need for companies to build strong pipelines, the industry's increasing investment in licensing deals must be matched with improved execution strategies.
Why buy this analysis?
- Understand why licensing agreements are failing to deliver the desired results
- Identify what types of licensing agreements are being made now, and understand the drivers that will determine investment in licensing deals over the next five years
- Improve your company's strategic approach to licensing agreements by evaluating our best practice recommendations
- Benchmark your licensing strategy, in terms of deal type and financial structure against those of the top 20 pharmaceutical companies
Scope and coverage
- Data on the large pharmaceutical companies that need to increase licensing activity from 2001 to 2007 to deliver double digit growth
- In-depth analysis of the deal trends for technology and product licensing agreements made by the top 20 pharmaceutical companies from 2000 to 2002
- Presents winning strategies that underpin the success of licensing agreements
- Assesses other options to traditional licensing agreements, including acquisition of a development partner, and negotiating access to a biotechnology company's pipeline of products
Report Methodology
Licensing Strategies contains extensive research and analysis of the licensing activity of large pharmaceutical companies. This included the compilation of a comprehensive licensing database containing all technology and product licensing agreements made by the top 20 pharmaceutical companies from 2000 to 2002.
In addition to this comprehensive data source, senior industry executives from leading pharmaceutical companies were interviewed as part of the research process and to validate all recommendations made.
'. Across the top 20 pharmaceutical companies, reliance on licensed drugs for sale is projected to increase from an average 14.8 per cent in 2001 to 19.1 per cent in 2007. '
Key findings and highlights
- Licensing is playing an increasing role in the business models of pharmaceutical and biotechnology companies. In 2001, 16.4 per cent of sales from the top 20 pharmaceutical company sales were derived from in-licensed drugs, equating to over $38 billion.
- More than one in three technology agreements made by large pharmaceutical companies since 2000 have involved target validation technologies.
- A typical upfront fee for phase III deals is approximately $110m.
- Cancer and CNS products are the most competitive areas for licensing agreements. This is because these therapy areas offer high market growth and high levels of unmet need.
'. We perform diligent NPV calculations for phase III deals but the greater number of uncertainties surrounding phase II deals makes the calculations less valid. '
Analysis structure
Problem Definition
- Why must large pharmaceutical companies conduct licensing agreements?
- Current attrition rates - why are deals going wrong?
- Drivers and resistors for pharmaceutical and biotechnology companies to enter licensing deals
Deal structure and value in discovery:
- Why are technology licensing deals so important?
- Technology deal trends
- Typical deal structures
- Expected return on investment
Deal structure and value in clinical development:
- Why are clinical licensing deals so important?
- Product licensing deal trends
- Typical deal structure
'. Cultural differences should be exploited. The innovative and fast moving atmosphere in small biotechs can rub off on large pharma, improving their productivity. '
Customers who bought this item also bought
Licensing Strategies - Examining Today�s Pharmaceutical Licensing Trends
Guide to Valuation of Pharmaceutical Licensing Deals
Evolving Trends in Biopharmaceutical Licensing: Deal Assessments, Drivers and Resistors
Licensing Strategies: Trends In The Top 20 Pharmaceutical Companies Activity
Valuing and Structuring Pharmaceutical Licensing Agreements
Bio-Device Licensing: Strategies for Success
Pharmaceutical Licensing Strategies: Best Practices in Deal-Making, Valuations and Strategic Management
Evolving Trends in Licensing: Strategies for Building and Retaining Value in Biotechnology Alliances
The Pharmaceutical Licensing Outlook: A Strategic Guide To Effective Deal-Making And Profitable Partnerships
Licensing Strategies for Accessing Biomarker Technologies
Licensing in Antibacterial R&D - Filling the Gaps
Biotechnology Licensing: How Has the Balance of Power Shifted?
|
|
|
|
